Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 15/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457805 | 1.00 | CYP1A2 (0.41) | CYP1A2CYP2C19MAPK14MAPK13MAPK12 | |
| SCHEMBL5455904 | 0.82 | MAPK14 (0.46) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL6568000 | 0.80 | MAPK14 (0.39) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL5458270 | 0.78 | MEN1 (0.38) | CYP1A2CYP2C19MAPK14TDP1MEN1 | |
| SCHEMBL5458267 | 0.78 | MEN1 (0.38) | CYP1A2CYP2C19MAPK14TDP1MEN1 | |
| SCHEMBL5458513 | 0.78 | MAPK14 (0.48) | CYP1A2CYP2C19MAPK14TDP1MEN1 | |
| SCHEMBL5458504 | 0.78 | MAPK14 (0.48) | CYP1A2CYP2C19MAPK14TDP1MEN1 | |
| SCHEMBL4469564 | 0.74 | PTGS2 (0.51) | CYP1A2CYP2C19TDP1MEN1KMT2A | |
| SCHEMBL4469574 | 0.74 | PTGS2 (0.51) | CYP1A2CYP2C19TDP1MEN1KMT2A | |
| SCHEMBL5459581 | 0.74 | TDP1 (0.42) | CYP1A2CYP2C19MAPK14TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232623-A1 | Pyrazolopyrimidine and Pyrazolotriazine Derivatives and Pharmaceutical Compositions Containing Them | GUDMUNDSSON KRISTJAN | 2007-10-04 | — | — | US | disclosed |
| US-7247626-B2 | Pyrazolopyrimidine derivatives and pharmaceutical compositions containing them | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1485385-B1 | PYRAZOLOPYRIMIDINE AND PYRAZOLOTRIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050124616-A1 | Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them | SMITHKLINE BEECHAM CORPORATION | 2005-06-09 | — | — | US | disclosed |
| EP-1485385-A1 | PYRAZOLOPYRIMIDINE AND PYRAZOLOTRIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SmithKline Beecham Corporation (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003076441-A1 | PYRAZOLOPYRIMIDINE AND PYRAZOLOTRIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124616-A1 | Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them | CYP3A5, CYP3A4, CYP3A7 | CYP1A2 16/4885CYP2C19 5/4885MAPK14 2705/4885 |
| US-20070232623-A1 | Pyrazolopyrimidine and Pyrazolotriazine Derivatives and Pharmaceutical Compositions Containing Them | CYP3A5, CYP3A4, CYP3A7 | CYP1A2 16/4885CYP2C19 5/4885MAPK14 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.